NCT04697069View on ClinicalTrials.gov

A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 4, 2021

Primary Completion Date

December 13, 2021

Study Completion Date

December 13, 2021

Conditions
Acneiform Eruptions
Interventions
BIOLOGICAL

Imsidolimab

Humanized monoclonal antibody

BIOLOGICAL

Placebo

Placebo

Trial Locations (18)

1038

Site 601, Riga

6000

Site 404, Batumi

33620

Site 102, Tampa

43215

Site 105, Columbus

63110

Site 101, St Louis

77030

Site 103, Houston

02215

Site 106, Boston

128 00

Site 302, New Town

656-91

Site 303, Brno

779 00

Site 301, Olomouc

305 99

Site 304, Plzen-Bory

0144

Site 402, Tbilisi

0160

Site 403, Tbilisi

Site 405, Tbilisi

0186

Site 401, Tbilisi

44-102

Site 204, Gliwice

60-569

Site 203, Poznan

70-784

Site 201, Szczecin

Sponsors
All Listed Sponsors
lead

Vanda Pharmaceuticals

INDUSTRY